Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RLMD |
---|---|---|
09:32 ET | 552 | 4.5 |
09:39 ET | 100 | 4.61 |
09:41 ET | 100 | 4.54 |
09:43 ET | 100 | 4.64 |
09:45 ET | 100 | 4.53 |
09:59 ET | 1650 | 4.62 |
10:01 ET | 1098 | 4.58 |
10:03 ET | 200 | 4.62 |
10:08 ET | 200 | 4.58 |
10:10 ET | 100 | 4.57 |
10:14 ET | 107 | 4.59 |
10:17 ET | 104 | 4.59 |
10:21 ET | 701 | 4.6 |
10:28 ET | 303 | 4.6 |
10:33 ET | 412 | 4.61 |
10:35 ET | 100 | 4.625 |
10:37 ET | 110 | 4.61 |
10:42 ET | 200 | 4.62 |
10:46 ET | 200 | 4.63 |
10:50 ET | 200 | 4.62 |
10:51 ET | 210 | 4.62 |
11:00 ET | 433 | 4.62 |
11:02 ET | 3447 | 4.62 |
11:04 ET | 200 | 4.62 |
11:06 ET | 100 | 4.62 |
11:08 ET | 100 | 4.6 |
11:09 ET | 26945 | 4.595 |
11:11 ET | 892 | 4.605 |
11:13 ET | 100 | 4.6 |
11:18 ET | 200 | 4.615 |
11:22 ET | 100 | 4.63 |
11:26 ET | 200 | 4.6 |
11:27 ET | 400 | 4.6 |
11:31 ET | 100 | 4.6 |
11:33 ET | 200 | 4.6 |
11:36 ET | 546 | 4.6 |
11:38 ET | 100 | 4.57 |
11:40 ET | 428 | 4.55 |
11:42 ET | 300 | 4.57 |
11:44 ET | 200 | 4.55 |
11:45 ET | 100 | 4.56 |
11:49 ET | 100 | 4.52 |
11:51 ET | 100 | 4.545 |
11:56 ET | 100 | 4.58 |
11:58 ET | 1294 | 4.55 |
12:03 ET | 400 | 4.59 |
12:07 ET | 200 | 4.57 |
12:09 ET | 500 | 4.59 |
12:12 ET | 100 | 4.585 |
12:16 ET | 200 | 4.55 |
12:20 ET | 100 | 4.55 |
12:21 ET | 700 | 4.57 |
12:25 ET | 100 | 4.57 |
12:27 ET | 300 | 4.59 |
12:30 ET | 700 | 4.59 |
12:32 ET | 358 | 4.59 |
12:34 ET | 200 | 4.58 |
12:36 ET | 3200 | 4.618 |
12:38 ET | 2031 | 4.64 |
12:39 ET | 600 | 4.61 |
12:43 ET | 500 | 4.59 |
12:50 ET | 200 | 4.59 |
12:56 ET | 200 | 4.575 |
12:59 ET | 100 | 4.56 |
01:01 ET | 1200 | 4.58 |
01:03 ET | 100 | 4.54 |
01:06 ET | 100 | 4.55 |
01:08 ET | 200 | 4.57 |
01:10 ET | 100 | 4.55 |
01:12 ET | 381 | 4.5344 |
01:14 ET | 310 | 4.5587 |
01:17 ET | 100 | 4.53 |
01:19 ET | 100 | 4.56 |
01:21 ET | 100 | 4.54 |
01:26 ET | 200 | 4.54 |
01:28 ET | 100 | 4.52 |
01:30 ET | 204 | 4.5259 |
01:32 ET | 200 | 4.545 |
01:33 ET | 100 | 4.51 |
01:35 ET | 100 | 4.52 |
01:37 ET | 100 | 4.55 |
01:39 ET | 100 | 4.53 |
01:44 ET | 629 | 4.535 |
01:46 ET | 2107 | 4.52 |
01:50 ET | 300 | 4.52 |
01:51 ET | 100 | 4.5 |
01:53 ET | 200 | 4.51 |
01:55 ET | 4000 | 4.56 |
02:00 ET | 100 | 4.53 |
02:02 ET | 770 | 4.54 |
02:08 ET | 400 | 4.56 |
02:09 ET | 100 | 4.565 |
02:13 ET | 300 | 4.5619 |
02:20 ET | 891 | 4.535 |
02:24 ET | 840 | 4.54 |
02:26 ET | 1500 | 4.5427 |
02:27 ET | 600 | 4.55 |
02:29 ET | 100 | 4.57 |
02:31 ET | 200 | 4.54 |
02:33 ET | 798 | 4.57 |
02:36 ET | 200 | 4.59 |
02:38 ET | 316 | 4.59 |
02:40 ET | 500 | 4.58 |
02:42 ET | 100 | 4.6 |
02:44 ET | 100 | 4.58 |
02:47 ET | 200 | 4.55 |
02:49 ET | 350 | 4.55 |
02:51 ET | 100 | 4.56 |
02:58 ET | 900 | 4.5714 |
03:00 ET | 100 | 4.57 |
03:07 ET | 100 | 4.58 |
03:09 ET | 100 | 4.57 |
03:12 ET | 500 | 4.59 |
03:16 ET | 150 | 4.61 |
03:20 ET | 200 | 4.62 |
03:23 ET | 100 | 4.63 |
03:27 ET | 100 | 4.6172 |
03:30 ET | 100 | 4.61 |
03:32 ET | 300 | 4.59 |
03:34 ET | 200 | 4.58 |
03:36 ET | 100 | 4.575 |
03:39 ET | 1450 | 4.58 |
03:41 ET | 600 | 4.5902 |
03:43 ET | 239 | 4.59 |
03:45 ET | 400 | 4.59 |
03:48 ET | 200 | 4.6 |
03:50 ET | 419 | 4.6 |
03:52 ET | 400 | 4.63 |
03:54 ET | 349 | 4.63 |
03:56 ET | 900 | 4.64 |
03:57 ET | 1500 | 4.615 |
03:59 ET | 1829 | 4.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Relmada Therapeutics Inc | 140.3M | -1.4x | --- |
Citius Pharmaceuticals Inc | 142.8M | -3.5x | --- |
CervoMed Inc | 143.8M | -7.2x | --- |
Vistagen Therapeutics Inc | 142.7M | -1.5x | --- |
Nuvectis Pharma Inc | 145.7M | -5.8x | --- |
Galectin Therapeutics Inc | 147.8M | -3.1x | --- |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $140.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.19 |
EPS | $-3.28 |
Book Value | $2.84 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.